SUPN
HealthcareSupernus Pharmaceuticals, Inc. · Drug Manufacturers - Specialty & Generic · $3B
What is Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals is a US-based biopharmaceutical company dedicated to developing and commercializing treatments for central nervous system diseases. Founded in 2012 and headquartered in Rockville, Maryland, the company has built a portfolio spanning epilepsy, Parkinson's disease, and ADHD.
Supernus generates revenue by commercializing branded CNS therapies in the United States. Its business model centers on extended-release formulations and specialty neurology products sold through targeted physician channels. The company also invests in late-stage pipeline candidates, including a drug-device combination for Parkinson's disease, aiming to expand its commercial footprint beyond its existing product lineup.
Supernus was founded in 2012 and operates from its headquarters in Rockville, US.
- Trokendi XR — extended-release topiramate for epilepsy and migraine prevention
- Oxtellar XR — extended-release oxcarbazepine for partial onset epilepsy
- Qelbree — norepinephrine reuptake inhibitor for pediatric ADHD
- APOKYN and XADAGO — therapies targeting off episodes in advanced Parkinson's disease
- MYOBLOC and GOCOVRI — treatments for cervical dystonia and Parkinson's-related dyskinesia
Is SUPN a Good Stock to Buy?
UQS Score rates SUPN as Below Average overall.
The Risk pillar stands out as the relative bright spot in SUPN's profile, suggesting the company carries a more manageable risk profile than its overall score might imply. Growth and Valuation both land at Neutral, meaning neither acts as a clear drag nor a standout positive at this time.
Both the Quality and Moat pillars register as Weak, pointing to limited competitive differentiation and below-average business quality metrics relative to sector peers — areas investors should weigh carefully.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SUPN pay dividends?
No — Supernus Pharmaceuticals, Inc. does not currently pay a dividend.
Supernus Pharmaceuticals does not currently pay a dividend. For a specialty biopharma at this stage, retaining capital to fund pipeline development, commercial expansion, and potential acquisitions is a common strategic choice. Income-focused investors should be aware that SUPN is not structured as a yield-generating holding.
When does SUPN report earnings?
Supernus Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
Quarterly results for SUPN tend to reflect the interplay between its established products and ongoing investment in pipeline and commercial infrastructure. Revenue trends across its CNS portfolio and operating cost discipline are the key variables to watch each reporting period.
For the most recent quarter's results, visit Supernus Pharmaceuticals' investor relations page directly.
SUPN Price History
+64.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Supernus Pharmaceuticals, Inc.?
Based on Supernus Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SUPN Long-term Outlook
With Growth rated Neutral and Risk rated Good, SUPN's fundamental outlook reflects a company that is neither accelerating sharply nor facing acute financial stress. The pipeline, particularly its late-stage Parkinson's candidate, represents a potential catalyst, though Weak Quality and Moat scores suggest the underlying business has not yet demonstrated durable earnings power. Execution on commercial products and pipeline milestones will be central to any meaningful re-rating.
Growth drivers
- Continued uptake of Qelbree in the pediatric ADHD market
- Potential approval and launch of the late-stage Parkinson's drug-device pipeline candidate
- Expansion of the Parkinson's disease portfolio through existing commercial products
Key risks
- Weak Moat rating signals limited pricing power and competitive differentiation
- Generic or branded competition in the extended-release epilepsy segment
- Pipeline execution risk tied to regulatory and clinical outcomes
SUPN vs Peers
Supernus operates in a competitive CNS and specialty pharma landscape alongside companies with differing geographic and therapeutic focuses.
Bausch Health is a much larger diversified specialty pharma company with a broader product portfolio spanning eye health, gastroenterology, and dermatology alongside CNS.
Curaleaf operates in the cannabis sector, representing an alternative approach to CNS-adjacent conditions through a very different regulatory and commercial framework.
HUTCHMED focuses primarily on oncology drug development in China and globally, competing for specialty pharma capital allocation rather than directly in CNS therapeutics.
Frequently Asked Questions
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases in the United States. Its marketed products address epilepsy, ADHD, and Parkinson's disease, with a late-stage pipeline targeting additional CNS indications.
Does SUPN pay dividends?
No, Supernus Pharmaceuticals does not currently pay a dividend. The company reinvests available capital into its commercial operations and pipeline development rather than returning cash to shareholders through distributions.
When does SUPN report earnings?
Supernus reports financial results on a quarterly basis, consistent with standard US-listed company practice. For exact dates and the most recent results, check the investor relations section of the Supernus Pharmaceuticals website.
Is SUPN a good stock to buy?
UQS Score rates SUPN as Below Average, driven by Weak Quality and Moat scores. The Risk pillar is rated Good, which provides some reassurance, but the overall profile suggests investors should review the full breakdown before drawing conclusions. Pro members can access the complete analysis.
Is SUPN overvalued?
The UQS Valuation pillar for SUPN is rated Neutral, meaning the stock does not appear obviously cheap or expensive relative to its fundamentals at this time. Valuation context is best interpreted alongside the Quality and Growth pillars — all available in the full UQS report.
How does SUPN compare to its competitors?
Supernus is a focused CNS specialty biopharma, which distinguishes it from larger diversified peers like Bausch Health. Its narrower therapeutic focus can be both a strength in execution and a vulnerability if key products face competitive pressure. The UQS platform allows side-by-side pillar comparisons.
What is SUPN's market cap bracket?
Supernus Pharmaceuticals is classified as a mid-cap company. This places it in a tier where growth potential and institutional coverage can be meaningful, but liquidity and scale are more limited than large-cap pharmaceutical peers.
Who founded Supernus Pharmaceuticals?
Supernus Pharmaceuticals was founded in 2012. Founding details and leadership history are publicly available through the company's official disclosures and investor relations materials.
Is SUPN a long-term quality investment?
As a long-term quality indicator, SUPN's Below Average UQS Score — anchored by Weak Quality and Moat ratings — suggests the company has not yet demonstrated the durable competitive advantages typically associated with high-conviction long-term holdings. Pipeline progress could change that picture over time.
What is the main competitive advantage of Supernus Pharmaceuticals?
Supernus has built expertise in extended-release CNS formulations and maintains an established commercial infrastructure in specialty neurology. However, the UQS Moat pillar is currently rated Weak, indicating this advantage has not yet translated into strong competitive differentiation by quantitative measures.
What sector does SUPN belong to?
Supernus Pharmaceuticals operates in the Healthcare sector, specifically within specialty biopharmaceuticals. Its focus on CNS diseases — epilepsy, Parkinson's disease, and ADHD — places it in the neurology-focused segment of the broader pharma industry.
Is SUPN a growth stock or value stock?
Based on UQS pillar labels, SUPN shows Neutral Growth and Neutral Valuation, making it difficult to categorize cleanly as either a pure growth or value play. It sits in a middle ground where pipeline execution will likely determine which label fits better over time.
Unlock Full SUPN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores
- ✓Access full financial metrics and quality indicators
- ✓Compare SUPN against sector peers side by side
- ✓Track pillar changes across quarterly updates
- ✓See the complete risk and valuation breakdown
- ✓Get the analyst-grade view in one dashboard
Pro Analysis
SUPN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | 41.1 | 19.9 | 27.0 | 56.6 | 72.0 | 48.4 | -0.6 |
| May 3, 2026 | 41.7 | 19.9 | 27.0 | 56.6 | 72.0 | 52.1 | +0.4 |
| May 1, 2026 | 41.3 | 19.9 | 27.0 | 56.6 | 72.0 | 50.1 | +0.3 |
| Apr 26, 2026 | 41.0 | 19.9 | 27.0 | 56.6 | 72.0 | 48.0 | +0.2 |
| Apr 19, 2026 | 40.8 | 19.9 | 27.0 | 56.6 | 72.0 | 46.4 | -0.2 |
| Apr 18, 2026 | 41.0 | 19.9 | 27.0 | 56.6 | 72.0 | 48.0 | -1.8 |
| Apr 14, 2026 | 42.8 | 19.9 | 27.0 | 56.6 | 72.0 | 60.0 | +0.1 |
| Apr 12, 2026 | 42.7 | 19.9 | 27.0 | 56.6 | 72.0 | 58.9 | 0.0 |
| Apr 11, 2026 | 42.7 | 19.9 | 27.0 | 56.6 | 72.0 | 59.1 | +0.1 |
| Apr 5, 2026 | 42.6 | 19.9 | 27.0 | 56.6 | 72.0 | 58.5 | +0.2 |
SUPN — Pillar Breakdown
Quality
— 22.8/100 (25%)Supernus Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 56.6/100 (20%)Supernus Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 72.6/100 (15%)Supernus Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 51.5/100 (15%)Supernus Pharmaceuticals, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 27/100 (25%)Supernus Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SUPN.
Score Composition
Financial Data
More Stock Analysis
How is the SUPN UQS Score Calculated?
The UQS (Unified Quality Score) for Supernus Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Supernus Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Supernus Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.